[Form 4] Cadrenal Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Matthew K. Szot, Chief Financial Officer of Cadrenal Therapeutics, Inc. (CVKD), reported sales of company common stock on two dates. On 09/24/2025 he sold 1,500 shares at a weighted average price of $13.9953, and on 09/25/2025 he sold 10,900 shares at a weighted average price of $14.0534, for a total of 12,400 shares sold. After these transactions the reporting person beneficially owned 18,933 shares, down from 29,833 shares following the first sale. The Form 4 is signed by the reporting person on 09/26/2025 and includes explanatory notes that the reported sales occurred in multiple transactions within the stated price ranges.

Positive

• Transactions are fully disclosed with dates, weighted-average prices, and post-transaction ownership stated
• Reporting person signed the Form 4 (09/26/2025) and included explanatory notes about price ranges

Negative

• Insider sold a total of 12,400 shares (1,500 on 09/24/2025 and 10,900 on 09/25/2025), reducing direct beneficial ownership to 18,933 shares
• Dispositions occurred over consecutive days, which materially decreased the reporting person's stake in the company

Insights

Securities Analyst

TL;DR: CFO executed disclosed sales totaling 12,400 shares across two days; holdings declined to 18,933 shares.

The Form 4 shows routine insider disposition rather than acquisitions or option exercises. The transactions are broken into two tranches: 1,500 shares at a weighted average of $13.9953 on 09/24/2025 and 10,900 shares at a weighted average of $14.0534 on 09/25/2025. The filing includes standard explanatory language about multiple sales within price ranges and is signed by the reporting person on 09/26/2025. For investors, the filing documents the precise amounts and prices but contains no additional operational or financial disclosures about the issuer.

Corporate Governance Expert

TL;DR: Disclosure is specific and signed; the sale materially reduced the insider's direct beneficial stake.

The report provides clear, itemized disclosure of the insider sales and remaining direct ownership: beneficial ownership is reported as 29,833 shares after the 09/24 tranche and 18,933 shares after the 09/25 tranche. The explanatory footnotes detail the price ranges and offer to provide trade-level breakdowns to regulators or the issuer, which is consistent with compliance practices. The filing does not state reasons for the sales or any change in role, and therefore governance implications are limited to the documented reduction in ownership.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Szot Matthew K

(Last) (First) (Middle)

C/O CADRENAL THERAPEUTICS, INC., 822

A1A NORTH, SUITE 306

(Street)

PONTE VEDRA FL 32082

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cadrenal Therapeutics, Inc. [ CVKD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/24/2025		S		1,500	D	$13.9953(1)	29,833	D
Common Stock	09/25/2025		S		10,900	D	$14.0534(2)	18,933	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of the Issuer's common stock sold by the Reporting Person in multiple transactions at prices ranging from $13.99 through $14.02, inclusive, having a weighted average price as shown in column 4 of $13.9953. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

2. Represents shares of the Issuer's common stock sold by the Reporting Person in multiple transactions at prices ranging from $13.99 through $14.52, inclusive, having a weighted average price as shown in column 4 of $14.0534. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

	/s/ Matthew K. Szot	09/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many shares did CVKD CFO Matthew K. Szot sell?

He sold 12,400 shares in total: 1,500 shares on 09/24/2025 and 10,900 shares on 09/25/2025.

At what prices were the CVKD shares sold?

Weighted average prices reported: $13.9953 for the 09/24 tranche and $14.0534 for the 09/25 tranche; price ranges are disclosed in the footnotes.

What was Matthew K. Szot's beneficial ownership after the sales?

Beneficial ownership reported as 18,933 shares following the 09/25/2025 transactions.

When was the Form 4 signed and filed by the reporting person?

The form is signed by Matthew K. Szot on 09/26/2025 as shown in the filing.

Does the Form 4 explain the trade-level breakdown of the sales?

Yes. Footnotes state the sales occurred in multiple transactions within stated price ranges and offer to provide full trade-level information upon request.